NCT03966443

Brief Summary

Comparison between image findings at aminoacid PET/CT and FDG PET/CT for myeloma patients

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
10

participants targeted

Target at below P25 for all trials

Timeline
33mo left

Started Mar 2019

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress72%
Mar 2019Jan 2029

Study Start

First participant enrolled

March 1, 2019

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

May 27, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 29, 2019

Completed
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 31, 2020

Completed
9 years until next milestone

Study Completion

Last participant's last visit for all outcomes

January 31, 2029

Expected
Last Updated

May 30, 2019

Status Verified

May 1, 2019

Enrollment Period

11 months

First QC Date

May 27, 2019

Last Update Submit

May 28, 2019

Conditions

Myeloma, MultiplePET-CT

Outcome Measures

Primary Outcomes (1)

  • Comparing of image findings at PET

    1 year

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Multiple myeloma patients

You may qualify if:

  • Multiple myeloma patients suitable for ASCT treatment

You may not qualify if:

  • Patients with contraindications to ASCT treatment

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Oslo University Hosptal

Oslo, 0424, Norway

RECRUITING

MeSH Terms

Conditions

Multiple Myeloma

Condition Hierarchy (Ancestors)

Neoplasms, Plasma CellNeoplasms by Histologic TypeNeoplasmsHemostatic DisordersVascular DiseasesCardiovascular DiseasesParaproteinemiasBlood Protein DisordersHematologic DiseasesHemic and Lymphatic DiseasesHemorrhagic DisordersLymphoproliferative DisordersImmunoproliferative DisordersImmune System Diseases

Central Study Contacts

Mona-Elisabeth Revheim, MD, PhD, MHA

CONTACT

+4790659373monar@ous-hf.no

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PI, MD, PhD, MHA

Study Record Dates

First Submitted

May 27, 2019

First Posted

May 29, 2019

Study Start

March 1, 2019

Primary Completion

January 31, 2020

Study Completion (Estimated)

January 31, 2029

Last Updated

May 30, 2019

Record last verified: 2019-05

Data Sharing

IPD Sharing
Will not share

Locations

NO(1)